Cargando…
TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT
In some types of cancer, telomere length is maintained by the alternative lengthening of telomeres (ALT) mechanism. In many ALT cancers, the α‐thalassemia/mental retardation syndrome X‐linked (ATRX) gene is mutated leading to the conclusion that the ATRX complex represses ALT. Here, we report that m...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549729/ https://www.ncbi.nlm.nih.gov/pubmed/35920001 http://dx.doi.org/10.15252/emmm.202215859 |
_version_ | 1784805734781812736 |
---|---|
author | de Nonneville, Alexandre Salas, Sébastien Bertucci, François Sobinoff, Alexander P Adélaïde, José Guille, Arnaud Finetti, Pascal Noble, Jane R Churikov, Dimitri Chaffanet, Max Lavit, Elise Pickett, Hilda A Bouvier, Corinne Birnbaum, Daniel Reddel, Roger R Géli, Vincent |
author_facet | de Nonneville, Alexandre Salas, Sébastien Bertucci, François Sobinoff, Alexander P Adélaïde, José Guille, Arnaud Finetti, Pascal Noble, Jane R Churikov, Dimitri Chaffanet, Max Lavit, Elise Pickett, Hilda A Bouvier, Corinne Birnbaum, Daniel Reddel, Roger R Géli, Vincent |
author_sort | de Nonneville, Alexandre |
collection | PubMed |
description | In some types of cancer, telomere length is maintained by the alternative lengthening of telomeres (ALT) mechanism. In many ALT cancers, the α‐thalassemia/mental retardation syndrome X‐linked (ATRX) gene is mutated leading to the conclusion that the ATRX complex represses ALT. Here, we report that most high‐grade pediatric osteosarcomas maintain their telomeres by ALT, and that the majority of these ALT tumors are ATRX wild‐type (wt) and instead carry an amplified 17p11.2 chromosomal region containing TOP3A. We found that TOP3A was overexpressed in the ALT‐positive ATRX‐wt tumors consistent with its amplification. We demonstrated the functional significance of these results by showing that TOP3A overexpression in ALT cancer cells countered ATRX‐mediated ALT inhibition and that TOP3A knockdown disrupted the ALT phenotype in ATRX‐wt cells. Moreover, we report that TOP3A is required for proper BLM localization and promotes ALT DNA synthesis in ALT cell lines. Collectively, our results identify TOP3A as a major ALT player and potential therapeutic target. |
format | Online Article Text |
id | pubmed-9549729 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95497292022-10-14 TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT de Nonneville, Alexandre Salas, Sébastien Bertucci, François Sobinoff, Alexander P Adélaïde, José Guille, Arnaud Finetti, Pascal Noble, Jane R Churikov, Dimitri Chaffanet, Max Lavit, Elise Pickett, Hilda A Bouvier, Corinne Birnbaum, Daniel Reddel, Roger R Géli, Vincent EMBO Mol Med Articles In some types of cancer, telomere length is maintained by the alternative lengthening of telomeres (ALT) mechanism. In many ALT cancers, the α‐thalassemia/mental retardation syndrome X‐linked (ATRX) gene is mutated leading to the conclusion that the ATRX complex represses ALT. Here, we report that most high‐grade pediatric osteosarcomas maintain their telomeres by ALT, and that the majority of these ALT tumors are ATRX wild‐type (wt) and instead carry an amplified 17p11.2 chromosomal region containing TOP3A. We found that TOP3A was overexpressed in the ALT‐positive ATRX‐wt tumors consistent with its amplification. We demonstrated the functional significance of these results by showing that TOP3A overexpression in ALT cancer cells countered ATRX‐mediated ALT inhibition and that TOP3A knockdown disrupted the ALT phenotype in ATRX‐wt cells. Moreover, we report that TOP3A is required for proper BLM localization and promotes ALT DNA synthesis in ALT cell lines. Collectively, our results identify TOP3A as a major ALT player and potential therapeutic target. John Wiley and Sons Inc. 2022-08-03 /pmc/articles/PMC9549729/ /pubmed/35920001 http://dx.doi.org/10.15252/emmm.202215859 Text en © 2022 The Authors. Published under the terms of the CC BY 4.0 license https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Articles de Nonneville, Alexandre Salas, Sébastien Bertucci, François Sobinoff, Alexander P Adélaïde, José Guille, Arnaud Finetti, Pascal Noble, Jane R Churikov, Dimitri Chaffanet, Max Lavit, Elise Pickett, Hilda A Bouvier, Corinne Birnbaum, Daniel Reddel, Roger R Géli, Vincent TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT |
title |
TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT
|
title_full |
TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT
|
title_fullStr |
TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT
|
title_full_unstemmed |
TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT
|
title_short |
TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT
|
title_sort | top3a amplification and atrx inactivation are mutually exclusive events in pediatric osteosarcomas using alt |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549729/ https://www.ncbi.nlm.nih.gov/pubmed/35920001 http://dx.doi.org/10.15252/emmm.202215859 |
work_keys_str_mv | AT denonnevillealexandre top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt AT salassebastien top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt AT bertuccifrancois top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt AT sobinoffalexanderp top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt AT adelaidejose top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt AT guillearnaud top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt AT finettipascal top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt AT noblejaner top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt AT churikovdimitri top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt AT chaffanetmax top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt AT lavitelise top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt AT picketthildaa top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt AT bouviercorinne top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt AT birnbaumdaniel top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt AT reddelrogerr top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt AT gelivincent top3aamplificationandatrxinactivationaremutuallyexclusiveeventsinpediatricosteosarcomasusingalt |